Robert Douglass

Strategic Sourcing
Novartis

Global supply chain management executive with a diversified background in the pharmaceutical, medical device, consumer, industrial products and hospitality industries. Core competency in manufacturing and global strategic sourcing using McKinsey model. Delivering constructive candor through leadership and planning.

Responsible for all chemical and packaging suppliers for all clinical studies being conducted by Cell and Gene Therapy Division
From supplier agreements to negotiating pricing and tracking performance like OTIF-on time in full. Involved with electronic bidding thru completion of Quality Agreements from supply chain perspective.

Check out the incredible speaker line-up to see who will be joining Robert.

Download The Latest Agenda

Supply Chain Effeciency Across the Global Network

Tuesday, May 9th, 2017

09:30 PANEL DISCUSSION: Pharma Supply Chains have Moved from Vertical to Network Environments – What Role does Supplier Relationship Management Play in this Transition?

With continued rise in the use of contract manufacturers, supply chain networks have become more complex then ever before. Traditionally, the supply chains built for vertical integration must be transitioned to a network environment. This panel will uncover how companies are managing that change. Historically, there has been hesitation to treating suppliers as strategic partners, but keeping them at arms length is a path to disaster. The panel will examine the following:

What are the fundamental success factors for a network environment?
What communication best practices within a network design?
What should the expectations be for suppliers within this new model?

15:15 Panel Discussion: What Does A Mature, Functioning Vendor Relationship Look Like Within An Emerging Market?

Emerging markets have been identified as an immediate source of growth as well as potential sources of supply. The cost, capacity and market-access benefits of these markets emerging market supply networks will be critically important to most large pharmacos over the next decade. The performance of those global networks tomorrow is rooted in the decisions companies make at home today

How should manufacturers be thinking about selecting supply partners when data on capabilities may not be available?
How to ensure a transparent relationship so that quality goals are met
Developing a hands-on approach to monitor supplier performance and manage the relationship